Syngeneic Graft Recipients
Syngeneic Graft Recipients - Related Videos
07:37
Mouse Models for Graft Arteriosclerosis
0 Views •
Cited by 17 •
2013
We describe protocols for our mouse graft arteriosclerois (GA) models which involve interposition of a mouse vessel segment into a recipient of the same inbred strain. By backcrossing additional genetic changes into the vessel donor, the model can assess the effect of specific genes on GA.
05:06
A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
0 Views •
Cited by 2 •
2015
The metastatic spread of cancer is the major cause of cancer-related deaths. We provide an in-depth description of our survival surgery methodology for establishing a “patient-like” orthotopic syngeneic mouse model system for studying the mechanisms of metastasis in solid organ tumors.
11:20
A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position
0 Views •
2022
We demonstrate how to establish a murine model of pulmonary root implantation into the descending aorta to simulate the Ross procedure. This model enables the medium/long-term evaluation of pulmonary autograft remodeling in a systemic position, representing the basis of developing therapeutic strategies to promote its adaptation.
05:47
Isolation and Transplantation of Different Aged Murine Thymic Grafts.
0 Views •
Cited by 14 •
2015
This report provides a detailed description of transplanting murine thymi from different aged donor mice under the kidney capsule of immunodeficient mouse recipients. The goal of this approach is to model T cell development and thymic selection events in vivo.
12:52
Conjugation: A Method to Transfer Ampicillin Resistance from Donor to Recipient E. coli
0 Views •
2023
Source: Alexander S. Gold1, Tonya M. Colpitts1 1 Department of Microbiology, Boston University School of Medicine, National Emerging Infections Diseases Laboratories, Boston, MA First discovered by Lederberg and Tatum in 1946, conjugation is a form of horizontal gene transfer between bacteria that relies on direct physical contact between two bacterial cells (1). Unlike other forms of gene transfer, such as transformation or transduction, conjugation is a naturally occurring process in which...
FAQs
Genetic matching minimizes immune activation directed at differences between donor tissue and recipient tissue. As a result, immune activity observed after tumor implantation is more likely to reflect recognition of tumor-associated antigens rather than rapid graft rejection. This separation helps researchers examine interactions between cancer cells and the host immune system under conditions that preserve immune competence.
The key difference is the source of genetic variation between donor and recipient. Allogeneic grafts carry genetic differences that can provoke incompatibility-related rejection, whereas syngeneic grafts avoid that confounding response. In cancer studies, this distinction allows tumor growth or treatment effects to be interpreted without attributing major findings to immune reactions against mismatched tissue.
Tumor antigens provide targets that the recipient’s immune system can recognize after implantation. Because graft incompatibility is minimized, immune-cell activity can be studied in relation to these cancer-associated signals rather than dominated by tissue mismatch. This makes the model useful for examining how tumors interact with immunity and how treatment may alter that interaction.
An immunocompetent setting retains the recipient’s capacity for immune-cell activity while tumor growth and treatment responses are evaluated. Researchers can therefore assess cancer behavior together with host immune responses, rather than examining tumor effects in isolation. This context is particularly relevant when the research question concerns immunotherapies or the relationship between tumor progression and antitumor immunity.
Researchers introduce compatible tumor cells or tissue into the recipient, then examine outcomes such as tumor growth, metastasis, immune-cell activity, or response to treatment. The compatible donor-recipient relationship establishes the experimental context, while subsequent observations connect tumor behavior with immune function. This workflow supports comparisons of untreated and treated animals within an immunocompetent cancer model.
The model can support evaluation of several linked outcomes, including how rapidly tumors grow, whether they metastasize, how immune cells respond, and whether an immunotherapy changes those patterns. Considering these outcomes together helps researchers distinguish a direct effect on cancer from an effect associated with graft incompatibility, improving interpretation of treatment-related findings.
They are especially useful when investigators need to study tumor biology and immune responses at the same time. The model supports research on tumor progression, metastasis, immune-cell activity, and immunotherapy response without the rapid rejection associated with genetic mismatch. It therefore provides a context for connecting treatment outcomes to interactions between cancer and a functioning host immune system.